Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study
- PMID: 39299922
- DOI: 10.1093/eurheartj/ehae575
Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study
Erratum in
-
Correction to: Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study.Eur Heart J. 2024 Oct 1:ehae693. doi: 10.1093/eurheartj/ehae693. Online ahead of print. Eur Heart J. 2024. PMID: 39352765 No abstract available.
Abstract
Background and aims: Prophylactic implantable cardioverter-defibrillators (ICDs) are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 to 90 days after an acute myocardial infarction. In the current therapeutic era, the prognosis of sustained ventricular arrhythmias (VAs) occurring during this early post-infarction phase (i.e. within 3 months of hospital discharge) has not yet been specifically evaluated in post-myocardial infarction patients with impaired LVEF. Such was the aim of this retrospective study.
Methods: Data analysis was based on a nationwide registry of 1032 consecutive patients with LVEF ≤ 35% after acute myocardial infarction who were implanted with an ICD after being prescribed a wearable cardioverter-defibrillator (WCD) for a period of 3 months upon discharge from hospital after the index infarction.
Results: ICDs were implanted either because a sustained VA occurred while on WCD (VA+/WCD, n = 72) or because LVEF remained ≤35% at the end of the early post-infarction phase (VA-/WCD, n = 960). The median follow-up was 30.9 months. Sustained VAs occurred within 1 year after ICD implantation in 22.2% and 3.5% of VA+/WCD and VA-/WCD patients, respectively (P < .0001). The adjusted multivariable analysis showed that sustained VAs while on WCD independently predicted recurrence of sustained VAs at 1 year (adjusted hazard ratio [HR] 6.91; 95% confidence interval [CI] 3.73-12.81; P < .0001) and at the end of follow-up (adjusted HR 3.86; 95% CI 2.37-6.30; P < .0001) as well as 1-year mortality (adjusted HR 2.86; 95% CI 1.28-6.39; P = .012).
Conclusions: In patients with LVEF ≤ 35%, sustained VA during the early post-infarction phase is predictive of recurrent sustained VAs and 1-year mortality.
Keywords: Myocardial infarction; Risk stratification; Sudden cardiac death; Ventricular fibrillation; Ventricular tachycardia; Wearable cardioverter–defibrillator.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.J Am Coll Cardiol. 2013 Nov 19;62(21):2000-2007. doi: 10.1016/j.jacc.2013.05.086. Epub 2013 Jul 31. J Am Coll Cardiol. 2013. PMID: 23916930
-
Effective treatment of electrical storm by a wearable cardioverter defibrillator in a patient with severely impaired left ventricular function after myocardial infarction: a case report.J Med Case Rep. 2021 May 17;15(1):243. doi: 10.1186/s13256-021-02833-2. J Med Case Rep. 2021. PMID: 33993888 Free PMC article.
-
Outcomes in patients with sustained ventricular tachyarrhythmias occurring within 48 h of acute myocardial infarction: when is ICD appropriate?Europace. 2014 Dec;16(12):1759-66. doi: 10.1093/europace/euu138. Epub 2014 Aug 6. Europace. 2014. PMID: 25100756
-
The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?Expert Rev Med Devices. 2016 Jul;13(7):627-32. doi: 10.1080/17434440.2016.1200969. Epub 2016 Jun 27. Expert Rev Med Devices. 2016. PMID: 27333818 Review.
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
Cited by
-
Implantable Cardioverter Defibrillators in Prevention of Sudden Cardiac Death in Kidney Transplant Recipients: A Case Series and an Appraisal of Current Evidence.J Clin Med. 2024 Sep 29;13(19):5820. doi: 10.3390/jcm13195820. J Clin Med. 2024. PMID: 39407880 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
